Agency offers guidance on office-based drug treatment for opioid addiction.
Mitka
Mike
M
D002047:Buprenorphine / Q000627:therapeutic use*; D006801:Humans; D009292:Narcotic Antagonists / Q000627:therapeutic use*; D009293:Opioid-Related Disorders / Q000188:drug therapy*; D014481:United States; D014482:United States Substance Abuse and Mental Health Services Administration
D009292:Narcotic Antagonists; D002047:Buprenorphine